(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Cyprus urges hotels to open up, pours funding into tourism - 2Extreme Manual for Purchasing Your Next Truck
- 3The most effective method to Remain Ahead in the Most recent Advanced Patterns with a Web based Advertising Degree
- 4Volunteers aiding humpback whale stranded in Baltic get death threats
- 56 Hints to Upgrade Your Appeal, In addition to Your Outlook
- Nigeria warns its citizens in South Africa to be cautious after march turns violent
- Astronauts' brains change shape and position after time in space, study finds
- Where should we send a real 'Hail Mary' spacecraft? A new study has the answers
- Oil magnate’s Venezuela detainment spooks industry
- 4 well known subjects in school
- NASA's make-or-break moon shot
- Ancient fire discovery marks significant milestone in human history
- Santa's sleigh or the International Space Station? How to spot a bright Christmas flyby Dec. 24 and 25
- 'Stranger Things' made him a heartthrob. He left Hollywood anyway.
